A phase 1 study of AMG 900, an orally administered pan‐aurora kinase inhibitor, in adult patients with acute myeloid leukemia

    loading  Checking for direct PDF access through Ovid

Abstract

Abstract unavailable for this article.

    loading  Loading Related Articles